Uno studio per valutare il TAR-210 rispetto al trattamento del cancro intravescicale con agente singolo nei partecipanti con cancro alla vescica (MoonRISe-1)
Uno studio randomizzato di fase 3 che valuta l'efficacia e la sicurezza del sistema di somministrazione intravescicale di Erdafitinib TAR-210 rispetto alla chemioterapia intravescicale con agente singolo in partecipanti con cancro della vescica non muscolo-invasivo a rischio intermedio (IR-NMIBC) e alterazioni FGFR suscettibili
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Buenos Aires, Argentina, C1419AHN
- Attivo, non reclutante
- Hospital Sirio Libanes
-
Chabas, Argentina, C1425
- Attivo, non reclutante
- Investigaciones Clinico Moleculares (ICM)
-
Córdoba, Argentina, 5000
- Attivo, non reclutante
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba, Argentina, X5000KPH
- Attivo, non reclutante
- Centro Urologico Profesor Bengio
-
Mar del Plata, Argentina, B7602
- Attivo, non reclutante
- Hospital Privado de la Comunidad
-
Rosario, Argentina, 2000
- Attivo, non reclutante
- Sanatorio de la Mujer
-
-
-
-
-
Graz, Austria, 8036
- Reclutamento
- Medizinische Universitaet Graz
-
Innsbruck, Austria, 6020
- Reclutamento
- Medizinische Universitat Innsbruck
-
Leopoldsdorf (Wien), Austria, 1090
- Reclutamento
- Medical University Vienna MUV
-
Linz, Austria, 4020
- Reclutamento
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg, Austria, 5020
- Reclutamento
- Universitaetsklinikum Salzburg Landeskrankenhaus
-
-
-
-
-
Aalst, Belgio, 9300
- Reclutamento
- AZORG campus Aalst Moorselbaan
-
Brugge (Bruges), Belgio, 8000
- Reclutamento
- AZ Sint-Jan
-
Edegem, Belgio, 2650
- Completato
- UZ Antwerpen
-
Gent (Ghent), Belgio, 9000
- Reclutamento
- AZ Maria Middelares
-
Leuven, Belgio, 3000
- Attivo, non reclutante
- Universitair Ziekenhuis Gasthuisberg
-
Sint-Niklaas, Belgio, 9100
- Reclutamento
- Vitaz
-
Yvoir, Belgio, 5530
- Reclutamento
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Barretos, Brasile, 14780-070
- Attivo, non reclutante
- Fundacao Pio XII
-
Campinas, Brasile, 13083-888
- Completato
- Universidade Estadual De Campinas
-
Natal, Brasile, 59062 000
- Attivo, non reclutante
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasile, 90035-001
- Attivo, non reclutante
- Hospital Moinhos de Vento
-
Porto Alegre, Brasile, 90050 170
- Attivo, non reclutante
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Salvador, Brasile, 41810-011
- Attivo, non reclutante
- HBA SA Assitencia Medica e Hospitalar
-
Santo André, Brasile, 09060-650
- Attivo, non reclutante
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasile, 01246-000
- Attivo, non reclutante
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brasile, 01509 900
- Completato
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasile, 01221-020
- Attivo, non reclutante
- Irmandade Santa Casa de Misericordia de Sao Paulo
-
São Paulo, Brasile, 01323 900
- Attivo, non reclutante
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Hradec Králové, Cechia, 500 05
- Completato
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Cechia, 779 00
- Reclutamento
- Fakultni nemocnice Olomouc
-
Prague, Cechia, 128 08
- Reclutamento
- Vseobecna fakultni nemocnice v Praze
-
Prague, Cechia, 150 06
- Reclutamento
- Fakultni nemocnice v Motole
-
Prague, Cechia, 140 59
- Reclutamento
- Fakultni Thomayerova nemocnice
-
-
-
-
-
Beijing, Cina, 100191
- Attivo, non reclutante
- Peking University Third Hospital
-
Beijing, Cina, 100050
- Attivo, non reclutante
- Beijing Friendship Hospital Capital Medical University
-
Changsha, Cina, 410013
- Attivo, non reclutante
- Hunan Cancer hospital
-
Chengdu, Cina, 610041
- Attivo, non reclutante
- West China School of Medicine/West China Hospital, Sichuan University
-
Chengdu, Cina, 610014
- Attivo, non reclutante
- The Third People's Hospital of Chengdu
-
Chongqing, Cina, 400033
- Attivo, non reclutante
- Chongqing Cancer Hospital
-
Fuzhou, Cina, 350001
- Attivo, non reclutante
- Fujian Medical University Union Hospital
-
Guangzhou, Cina, 510060
- Attivo, non reclutante
- Sun Yat Sen University Cancer Center
-
Nanjing, Cina, 210008
- Attivo, non reclutante
- Nanjing Drum Tower Hospital
-
Nanjing, Cina, 210009
- Attivo, non reclutante
- Zhongda Hospital Southeast University
-
Shanghai, Cina, 200031
- Attivo, non reclutante
- Huadong Hospital Affiliated to Fudan University
-
Tianjin, Cina, 300061
- Attivo, non reclutante
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Cina, 325000
- Attivo, non reclutante
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Cina, 430032
- Attivo, non reclutante
- Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Xinshi, Cina, 710063
- Attivo, non reclutante
- The First Affiliated Hospital of Xian Jiaotong University
-
Xuzhou, Cina, 221004
- Attivo, non reclutante
- The Affiliated Hospital of Xuzhou Medical University
-
Ürümqi, Cina, 830011
- Attivo, non reclutante
- Cancer Hospital of Xinjiang Medical University
-
-
-
-
-
Chuncheon, Corea del Sud, 28644
- Completato
- Chungbuk National University Hospital
-
Gyeongin, Corea del Sud, 10408
- Reclutamento
- National Cancer Center
-
Sangam-dong, Corea del Sud, 58128
- Reclutamento
- Chonnam National University Hwasun Hospital
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
Seoul, Corea del Sud, 3080
- Reclutamento
- Seoul National University Hospital
-
Seoul, Corea del Sud, 06591
- Attivo, non reclutante
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Aarhus, Danimarca, 8200
- Reclutamento
- Aarhus University Hospital
-
Copenhagen, Danimarca, 2100
- Reclutamento
- Rigshospitalet
-
Herlev, Danimarca, 2730
- Reclutamento
- Herlev Hospital
-
Odense, Danimarca, 5000
- Reclutamento
- Odense Universitetshospital
-
Roskilde, Danimarca, 4000
- Reclutamento
- Zealand University Hospital
-
-
-
-
-
Lille, Francia, 59000
- Completato
- Hospital Center University De Lille
-
Limoges, Francia, 87000
- Reclutamento
- Polyclinique de Limoges - Francois Chenieux
-
Lyon, Francia, 69003
- Reclutamento
- Hôpital Edouard Herriot
-
Marseille, Francia, 13009
- Reclutamento
- Institut Paoli Calmettes
-
Paris, Francia, 75010
- Reclutamento
- Hopital Saint Louis
-
Paris, Francia, 75013
- Reclutamento
- CHU Pitie Salpetriere
-
Paris, Francia, 75018
- Reclutamento
- APHP - Hopital Bichat - Claude Bernard
-
Quint-Fonsegrives, Francia, 31130
- Reclutamento
- Clinique de la Croix du Sud
-
Rennes, Francia, 35000
- Completato
- Chu Rennes Hopital Pontchaillou
-
Toulouse, Francia, 31059
- Reclutamento
- CHU Rangueil
-
Villejuif, Francia, 94805
- Reclutamento
- Institut Gustave Roussy
-
-
-
-
-
Berlin, Germania, 10117
- Attivo, non reclutante
- Charite - Universitaetsmedizin Berlin (CCM)
-
Braunschweig, Germania, 38126
- Reclutamento
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Cologne, Germania, 50968
- Reclutamento
- Studienzentrum Bayenthal
-
Dresden, Germania, 01307
- Completato
- Urologische Gemeinschaftspraxis
-
Frankfurt am Main, Germania, 60596
- Reclutamento
- Universitaetsklinikum Frankfurt
-
Hamburg, Germania, 22081
- Attivo, non reclutante
- Urologikum Hamburg MVZ - Germany
-
Herne, Germania, 44625
- Reclutamento
- Marien hospital Herne
-
Jena, Germania, 07747
- Attivo, non reclutante
- Universitatsklinikum Jena
-
München, Germania, 81675
- Completato
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Straubing, Germania, 94315
- Reclutamento
- Klinikum St. Elisabeth Straubing GmbH
-
Stuttgart, Germania, 70174
- Completato
- Katharinenhospital Innere Medizin
-
-
-
-
-
Amagasaki, Giappone, 660 8550
- Attivo, non reclutante
- Hyogo Prefectural Amagasaki General Medical Center
-
Kawasaki, Giappone, 216 8511
- Reclutamento
- St Marianna University Hospital
-
Kobe, Giappone, 650 0047
- Attivo, non reclutante
- Kobe City Medical Center General Hospital
-
Kumamoto, Giappone, 860 0008
- Attivo, non reclutante
- National Hospital Organization Kumamoto Medical Center
-
Osaka, Giappone, 541 8567
- Reclutamento
- Osaka International Cancer Institute
-
Saitama, Giappone, 350 8550
- Attivo, non reclutante
- Saitama Medical Center
-
Wakayama, Giappone, 640 8558
- Attivo, non reclutante
- JRC Wakayama Medical Center
-
Yokohama, Giappone, 221 0855
- Reclutamento
- Yokohama Municipal Citizen's Hospital
-
Yokohama, Giappone, 232 0024
- Attivo, non reclutante
- Yokohama City University Medical Center
-
Yokosuka, Giappone, 238 8558
- Reclutamento
- Yokosuka Kyosai Hospital
-
Ōta-ku, Giappone
- Reclutamento
- Gunma Prefectural Cancer Center
-
-
-
-
-
Hong Kong, Hong Kong
- Attivo, non reclutante
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Attivo, non reclutante
- Prince Of Wales Hospital
-
-
-
-
-
Cork, Irlanda, T12 DC4A
- Attivo, non reclutante
- Cork University Hospital
-
Dublin, Irlanda, D07 A8NN
- Attivo, non reclutante
- Mater Misericordiae University Hospital
-
Dublin, Irlanda, D07 WKW8
- Attivo, non reclutante
- Mater Private Hospital
-
Dublin, Irlanda, D24 NR0A
- Attivo, non reclutante
- Adelaide and Meath Hospital
-
-
-
-
-
Haifa, Israele, 3109601
- Reclutamento
- Rambam Health Care Campus
-
Ramat Gan, Israele, 52621
- Reclutamento
- Sheba Medical Center
-
Sderot, Israele, 13100
- Reclutamento
- Ziv Medical Center
-
Tel Aviv, Israele, 6423906
- Reclutamento
- Sourasky Medical Center
-
Yeruham, Israele, 9112001
- Completato
- Hadassah University Hospita Ein Kerem
-
-
-
-
-
Arezzo, Italia, 52100
- Reclutamento
- Ospedale S. Donato Arezzo, USL 8 - U.O. Oncologia Medica
-
Bergamo, Italia, 24125
- Reclutamento
- Cliniche Humanitas Gavazzeni
-
Brescia, Italia, 25123
- Reclutamento
- ASST Spedali Civili Brescia
-
Milan, Italia, 20133
- Reclutamento
- Istituto Dei Tumori Di Milano
-
Milan, Italia, 20132
- Completato
- Ospedale San Raffaele
-
Romagnano, Italia, 00128
- Reclutamento
- Universita Campus Bio-Medico di Roma
-
Romagnano, Italia, 00144
- Reclutamento
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Italia, 20089
- Reclutamento
- Istituto Clinico Humanitas
-
Torino, Italia, 10126
- Reclutamento
- A.O.Citta della Salute e della Scienza di Torino
-
-
-
-
-
Bialystok, Polonia, 15 276
- Attivo, non reclutante
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polonia, 85 048
- Attivo, non reclutante
- IN VIVO Sp. z o.o
-
Bydgoszcz, Polonia, 85 796
- Completato
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Lublin, Polonia, 20 090
- Attivo, non reclutante
- Uniwersytecki Szpital Kliniczny nr 4
-
Przemyśl, Polonia, 37 700
- Attivo, non reclutante
- Wojewodzki Szpital im Sw Ojca Pio w Przemyslu
-
Tarnów, Polonia, 33-100
- Attivo, non reclutante
- Szpital Wojewodzki Im Sw Lukasza Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Tarnowie
-
Torun, Polonia, 87-100
- Completato
- Medicover Integrated Clinical Services Sp z o o
-
Wiele, Polonia, 05-135
- Attivo, non reclutante
- Mazowiecki Szpital Onkologiczny Sp z o o
-
Wroclaw, Polonia, 50 981
- Completato
- 4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
-
Wroclaw, Polonia, 53-413
- Attivo, non reclutante
- Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii
-
-
-
-
-
Bristol, Regno Unito, BS105NB
- Attivo, non reclutante
- Southmead Hospital
-
London, Regno Unito, W6 8RF
- Attivo, non reclutante
- Charing Cross Hospital
-
London, Regno Unito, EC1A 7BE
- Attivo, non reclutante
- St Bartholomews Hospital
-
Newcastle upon Tyne, Regno Unito, NE7 7DN
- Attivo, non reclutante
- Newcastle Freeman Hospital
-
Sheffield, Regno Unito, S10 2SJ
- Attivo, non reclutante
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Southampton, Regno Unito, SO16 6YD
- Attivo, non reclutante
- Southampton General Hospital
-
Sutton, Regno Unito, SM2 5PT
- Attivo, non reclutante
- Royal Marsden Hospital
-
-
-
-
-
Alzira, Spagna, 46600
- Reclutamento
- Hosp. Univ. de La Ribera
-
Barcelona, Spagna, 08025
- Reclutamento
- Fund. Puigvert
-
Barcelona, Spagna, 08036
- Reclutamento
- Hosp Clinic de Barcelona
-
Barcelona, Spagna, 08035
- Completato
- Hosp Univ Vall D Hebron
-
Cadiz, Spagna, 11009
- Reclutamento
- Hosp. Puerta Del Mar
-
Castillón, Spagna, 12004
- Reclutamento
- Hosp. Gral. Univ. de Castellon
-
Jerez de la Frontera, Spagna, 11407
- Reclutamento
- Hosp. de Jerez de La Frontera
-
La Coruña (A Coruña), Spagna, 15006
- Reclutamento
- Hosp Univ A Coruna
-
Madrid, Spagna, 28041
- Reclutamento
- Hosp. Univ. 12 de Octubre
-
Madrid, Spagna, 28027
- Reclutamento
- Clinica Univ. de Navarra
-
Madrid, Spagna, 28007
- Completato
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga, Spagna, 29010
- Reclutamento
- Hosp Virgen de La Victoria
-
Oviedo, Spagna, 33011
- Completato
- Hosp. Univ. Central de Asturias
-
Sabadell, Spagna, 08208
- Reclutamento
- Hosp.Univ.Parc Tauli
-
Seville, Spagna, 41013
- Completato
- Hosp. Virgen Del Rocio
-
Valencia, Spagna, 46010
- Reclutamento
- Hosp. Clinico Univ. de Valencia
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72211
- Completato
- Arkansas Urology
-
-
California
-
Los Alamitos, California, Stati Uniti, 90720
- Attivo, non reclutante
- Genesis Research LLC
-
Los Angeles, California, Stati Uniti, 90033
- Attivo, non reclutante
- USC Norris Comprehensive Cancer Center
-
Orange, California, Stati Uniti, 92868
- Attivo, non reclutante
- University of California Irvine Medical Center
-
San Diego, California, Stati Uniti, 92123
- Attivo, non reclutante
- Om Research LLC
-
Sherman Oaks, California, Stati Uniti, 91411
- Completato
- Genesis Research LLC 1
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Completato
- University of Colorado Cancer Center Anschultz Cancer Pavilion
-
Lakewood, Colorado, Stati Uniti, 80228
- Attivo, non reclutante
- Colorado Clinical Research
-
San Luis, Colorado, Stati Uniti, 63141
- Completato
- Mercy Research
-
San Luis, Colorado, Stati Uniti, 63141
- Attivo, non reclutante
- Specialty Clinical Research of St Louis
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Attivo, non reclutante
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Completato
- Northwestern University
-
-
Indiana
-
Jeffersonville, Indiana, Stati Uniti, 47130
- Completato
- First Urology
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67226
- Attivo, non reclutante
- Wichita Urology Group
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70121-2429
- Attivo, non reclutante
- Ochsner Health System
-
-
Maryland
-
Hanover, Maryland, Stati Uniti, 21076
- Completato
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Completato
- Brigham And Women's Hospital
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Attivo, non reclutante
- Karmanos Cancer Institute
-
Royal Oak, Michigan, Stati Uniti, 48073
- Attivo, non reclutante
- Comprehensive Urology
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Attivo, non reclutante
- The Urology Center, PC
-
-
New Jersey
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Attivo, non reclutante
- Cancer Institute Of New Jersey
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Attivo, non reclutante
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10016
- Completato
- Integrated Medical Professionals
-
Syracuse, New York, Stati Uniti, 13210
- Attivo, non reclutante
- SUNY Upstate Med Univ
-
Syracuse, New York, Stati Uniti, 13210
- Attivo, non reclutante
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28204
- Attivo, non reclutante
- Levine Cancer Institute
-
Raleigh, North Carolina, Stati Uniti, 27612
- Attivo, non reclutante
- Associated Urologists of North Carolina
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Stati Uniti, 19004
- Completato
- MidLantic Urology
-
Lancaster, Pennsylvania, Stati Uniti, 17604
- Attivo, non reclutante
- Keystone Urology Specialists
-
-
South Carolina
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Attivo, non reclutante
- Carolina Urologic Research Center
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti, 38138
- Attivo, non reclutante
- The Conrad Pearson Clinic
-
Knoxville, Tennessee, Stati Uniti, 37920
- Completato
- University of Tennessee Medical Center
-
Nashville, Tennessee, Stati Uniti, 37209
- Attivo, non reclutante
- Urology Associates
-
-
Texas
-
Austin, Texas, Stati Uniti, 78745
- Attivo, non reclutante
- Urology Austin
-
Dallas, Texas, Stati Uniti, 75231
- Attivo, non reclutante
- Urology Clinics of North Texas
-
Dallas, Texas, Stati Uniti, 75390
- Completato
- UT Southwestern
-
Houston, Texas, Stati Uniti, 77027
- Attivo, non reclutante
- Houston Metro Urology
-
-
Washington
-
Spokane, Washington, Stati Uniti, 99202
- Attivo, non reclutante
- Spokane Urology
-
-
-
-
-
?zmir, Turchia (Türkiye), 35330
- Reclutamento
- Dokuz Eylul University Medical Faculty
-
Adana, Turchia (Türkiye), 01120
- Completato
- Adana Baskent Practice and Research Hospital
-
Ankara, Turchia (Türkiye), 06200
- Reclutamento
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turchia (Türkiye), 06100
- Completato
- Ankara University Medical Faculty
-
Istanbul, Turchia (Türkiye), 34722
- Reclutamento
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul, Turchia (Türkiye), 34153
- Completato
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul, Turchia (Türkiye), 34865
- Reclutamento
- Kartal Dr Lutfi Kirdar sehir Hastanesi
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Main study only: Have a histologically confirmed diagnosis (within 90 days of randomization) of IR-NMIBC with at least one of the following criteria fulfilled: a. Ta low grade (LG)/ Grade 1 (G1): primary or recurrent, b. Ta LG/G2: primary or recurrent and c. Greater than or equal to (>=) 1 of the following risk factors: i. Multiple Ta LG tumors, ii. Solitary LG tumor >= 3 cm, iii. Early recurrence (less than [<] 1 year), iv. Frequent recurrence (greater than [>] 1 per year), v. Recurrence after prior adjuvant intravesical treatment (single perioperative dose of chemotherapy does not fulfill this risk factor)
- Substudy only: Have a histologically confirmed new diagnosis (within 90 days of randomization) of IR-NMIBC for whom MMC is deemed the therapy of choice according to local standard of care with at least 1 of the following criteria fulfilled: a. Ta LG/G1, b. Ta LG/G2, and >=1 of the following risk factors: i) Multiple Ta LG tumors, ii) Solitary LG tumor >=3 cm
- Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing
- Participants must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for assessment of recurrence/progression) and receive the assigned treatment, including intravesical chemotherapy if randomized into that arm.
- Visible papillary disease must be fully resected prior to randomization and absence of disease must be documented at Screening cystoscopy
- Can have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Have an Eastern Cooperative Oncology Group performance status of 0 to 2
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to any study component or its excipients, including: a. Erdafitinib excipients; b.TAR-210 drug delivery system constituent materials ; c. urinary placement catheter materials; d. MMC or chemically related drugs; e. Gemcitabine or chemically related drugs
- Presence of any bladder or urethral anatomic feature (that is, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-210 or passage of a urethral catheter for intravesical chemotherapy
- Polyuria with recorded 24-hour urine volumes > 4000 milliliters (mL)
- Current indwelling urinary catheters, however, intermittent catheterization is acceptable
- Had major surgery or had significant traumatic injury and/or not fully recovered within 4 weeks before first dose (TURBT is not considered major surgery)
Substudy:
- Previous diagnosis of histologically confirmed urothelial bladder carcinoma at any time prior to current qualifying diagnosis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Main Study: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Altri nomi:
|
|
Comparatore attivo: Main Study: Group B: MMC or Gemcitabine
Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
Gemcitabine will be administered intravesically. MMC will be administered intravesically. |
|
Sperimentale: Substudy: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Altri nomi:
|
|
Comparatore attivo: Substudy: Group B: MMC
Participants in substudy Group B will receive intravesical MMC once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
MMC will be administered intravesically. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease Free Survival (DFS)
Lasso di tempo: From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
DFS is measured as the time from randomization to the date of the first documented recurrence of Ta non-muscle invasive bladder cancer (NMIBC) of any grade, disease progression, or death due to any cause, whichever occurs first. |
From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to next Treatment (TTNT)
Lasso di tempo: From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
TTNT is measured as the time from randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer. |
From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
|
High Grade Recurrence-free Survival (HG RFS)
Lasso di tempo: From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
HG RFS is measured as the time from randomization to the date of first documented evidence of HG NMIBC or death, whichever occurs first |
From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
|
Progression Free Survival (PFS)
Lasso di tempo: From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
PFS is measured as the time from randomization to the date of first documented evidence of disease progression or death, whichever occurs first. |
From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
|
Number of Diagnostic and Therapeutic Invasive Urological Interventions after Study Treatment
Lasso di tempo: From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
Number of diagnostic and therapeutic invasive urological interventions after study treatment, that is, endoscopic procedures (e.g., cystoscopies, transurethral resection of bladder tumors (TURBTs), ureteroscopies, urethral interventions, urethral stricture/bladder neck incision), catheterization (intravesical, suprapubic), intravesical treatments, major surgeries (e.g., radical cystectomy, simple cystectomy, urethroplasty) will be reported. |
From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
|
Number of Participants With Adverse Events (Including Physical Examination, Vital Signs and Laboratory Abnormalities)
Lasso di tempo: From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
An AE is any untoward medical occurrence in a participant participating in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product, that does not necessarily have a causal relationship with the treatment. AEs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening and Grade 5: Death. Number of participants with adverse events (including physical examination, vital signs and laboratory abnormalities) will be reported. |
From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
|
Overall Survival (OS)
Lasso di tempo: From randomization to the date of death (approximately 4 years and 2 months)
|
OS is defined as the time from randomization to the date of death from any cause. |
From randomization to the date of death (approximately 4 years and 2 months)
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores
Lasso di tempo: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores
Lasso di tempo: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-C30 Scores
Lasso di tempo: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the HRQoL of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-NMIBC24 Scores
Lasso di tempo: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie urologiche
- Carcinoma
- Malattie della vescica urinaria
- Neoplasie della vescica urinaria
- Neoplasie vescicali non muscolo invasive
- Composti eterociclici, 1-anello
- Composti eterociclici
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Gemcitabina
- erdafitinib
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 42756493BLC3004
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .